慢性肾脏病肾性贫血药物治疗研究进展

doi:10.3969/j.issn.1674-490X.2022.06.003

摘要/Abstract

摘要： 慢性肾脏病(chronic kidney disease,CKD)是一种慢性长期进展性疾病,是全球性公共卫生问题之一。肾性贫血作为CKD常见并发症之一,其患病率随CKD疾病进展而逐渐升高。肾性贫血可导致组织缺血、缺氧进而引发呼吸衰竭、心力衰竭等一系列并发症,进而加重CKD病情,严重时可危及患者生命。因此,纠正肾性贫血是CKD治疗中非常重要的一部分。临床上常规纠正贫血的治疗方法有补充红细胞生成刺激剂(erythropoiesis-stimulating agents,ESAs)、铁剂、左卡尼汀、输血等,但常规治疗方法的局限性日益增多。近年来,低氧诱导因子脯氨酰羟化酶抑制剂作为一种新型口服药物备受关注,在治疗肾性贫血中具有多种优势,目前已逐渐成为临床治疗肾性贫血的新一线用药。现综述肾性贫血药物治疗研究进展。

关键词: 肾性贫血, 红细胞生成刺激剂, 铁剂, 左卡尼汀, 低氧诱导因子脯氨酰羟化酶抑制剂

Abstract: Chronic kidney disease(CKD)is a chronic and long-term progressive disease and one of the global public health problems. Renal anemia is one of the common complications of CKD, and its prevalence rate gradually increases with the development of CKD. Renal anemia can lead to tissue ischemia and hypoxia, leading to a series of complications such as respiratory failure and heart failure. At the same time, it aggravates the condition of CKD, and in severe cases, it can endanger patients' lives. Therefore, the correction of renal anemia is a very important part in the treatment of CKD. Routine clinical methods for correcting anemia include supplementing erythropoiesis-stimulants(ESAs), iron, L-carnitineand blood transfusion, but their limitations are increasing. In recent years, hypoxia-inducible factor proline hydroxylase inhibitors, as a new oral drug, has attracted much attention,which has multiple advantages in the treatment of renal anemia, and now it has gradually become a new first-line drug in clinical treatment of renal anemia. This article reviews the recent developments of drug therapy for renal anemia.

Key words: renal anemia, erythropoiesis-stimulating agents, iron agent, L-carnitine, hypoxia-inducible factor proline hydroxylase inhibitor

中图分类号:

段雪婷,李叶,张思,王倩,张海松,高燕. 慢性肾脏病肾性贫血药物治疗研究进展[J]. 医学研究与教育, 2022, 39(6): 15-23.

参考文献

[1] GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the global burden of disease study 2017[J]. Lancet, 2020, 395(10225): 709-733. DOI: 10.1016/S0140-6736(20)30045-3.
[2] 肾性贫血诊断和治疗共识中国专家组.肾性贫血诊断与治疗中国专家共识[J].中华肾脏病杂志, 2013, 29(5): 389-392. DOI: 10.3760/cma.j.issn.1001-7097.2013.05.017.
[3] SHIFERAW W S, AKALU T Y, AYNALEM Y A. Risk factors for Anemia in patients with chronic renal failure: a systematic review and meta-analysis[J]. Ethiop J Health Sci, 2020, 30(5): 829-842. DOI: 10.4314/ejhs.v30i5.23.
[4] KURATA Y, TANAKA T, NANGAKU M. An evaluation of roxadustat for the treatment of Anemia associated with chronic kidney disease[J]. Expert Opin Pharmacother, 2022, 23(1): 19-28. DOI: 10.1080/14656566.2021.1993821.
[5] LOCATELLI F, DEL VECCHIO L, DE NICOLA L, et al. Are all erythropoiesis-stimulating agents created equal? [J]. Nephrol Dial Transplant, 2021, 36(8): 1369-1377. DOI: 10.1093/ndt/gfaa034.
[6] FULLER D S, ROBINSON B M, LOCATELLI F, et al. Patterns of erythropoiesis-stimulating agent use in European hemodialysis patients: the dialysis outcomes and practice patterns study[J]. Nephron, 2018, 140(1): 24-30. DOI: 10.1159/000490202.
[7] 中国医师协会肾脏内科医师分会肾性贫血指南工作组.中国肾性贫血诊治临床实践指南[J].中华医学杂志,2021,101(20):1463-1502.DOI: 10.3760/cma.j.cn112137-20210201-00309.
[8] SPOTO B, KAKKAR R, LO L, et al. Serum erythroferrone levels associate with mortality and cardiovascular events in hemodialysis and in CKD patients: a two cohorts study[J]. J Clin Med, 2019, 8(4): 523. DOI: 10.3390/jcm8040523.
[9] GUPTA A, PRATT R, MISHRA B. Physicochemical characterization of ferric pyrophosphate citrate[J]. Biometals, 2018, 31(6): 1091-1099. DOI: 10.1007/s10534-018-0151-1.
[10] WUNDERER F, TRAEGER L, SIGURSLID H H, et al. The role of hepcidin and iron homeostasis in atherosclerosis[J]. Pharmacol Res, 2020, 153: 104664. DOI: 10.1016/j.phrs.2020.104664.
[11] 中华医学会肾脏病学分会肾性贫血诊断和治疗共识专家组.肾性贫血诊断与治疗中国专家共识(2018修订版)[J].中华肾脏病杂志,2018,34(11):860-866.DOI: 10.3760/cma.j.issn.1001-7097.2018.11.012.
[12] AGARWAL A K. Iron metabolism and management: focus on chronic kidney disease[J]. Kidney Int Suppl(2011), 2021, 11(1): 46-58. DOI: 10.1016/j.kisu.2020.12.003.
[13] MACDOUGALL I C, WHITE C, ANKER S D, et al. Intravenous iron in patients undergoing maintenance hemodialysis[J]. N Engl J Med, 2019, 380(5): 447-458. DOI: 10.1056/NEJMoa1810742.
[14] PERGOLA P E, KOPYT N P. Oral ferric maltol for the treatment of iron-deficiency Anemia in patients with CKD: a randomized trial and open-label extension[J]. Am J Kidney Dis, 2021, 78(6): 846-856.e1. DOI: 10.1053/j.ajkd.2021.03.020.
[15] NAH E H, CHO S, KIM S, et al. Distribution of hemoglobin levels and prevalence of Anemia according to sex, age group, and region in 13 Korean cities[J]. Int J Lab Hematol, 2020, 42(2): 223-229. DOI: 10.1111/ijlh.13160.
[16] KHOURY A, PAGAN K A, FARLAND M Z. Ferric maltol: a new oral iron formulation for the treatment of iron deficiency in adults[J]. Ann Pharmacother, 2021, 55(2): 222-229. DOI: 10.1177/1060028020941014.
[17] 王文沛,张斌,张海英.新型三价铁化合物麦芽酚铁的临床评价[J].临床药物治疗杂志, 2020, 18(11): 5-9. DOI: 10.3969/j.issn.1672-3384.2020.11.002.
[18] ABBATI G, INCERTI F, BOARINI C, et al. Safety and efficacy of sucrosomial iron in inflammatory bowel disease patients with iron deficiency Anemia[J]. Intern Emerg Med, 2019, 14(3): 423-431. DOI: 10.1007/s11739-018-1993-9.
[19] FABIANO A, BRILLI E, FOGLI S, et al. Sucrosomial^® iron absorption studied by in vitro and ex-vivo models[J]. Eur J Pharm Sci, 2018, 111: 425-431. DOI: 10.1016/j.ejps.2017.10.021.
[20] 万洪聘,罗敏,张剑彬.柠檬酸铁治疗慢性肾脏病患者的疗效及安全性的Meta分析[J].临床肾脏病杂志, 2021, 21(5): 358-368. DOI:10.3969/j.issn.1671-2390.m20-170.
[21] 陈敏.羧基麦芽糖铁的临床研究进展[J].药学与临床研究, 2021, 29(2): 117-121. DOI: 10.13664/j.cnki.pcr.2021.02.009.
[22] BAZELEY J W, WISH J B. Recent and emerging therapies for iron deficiency in Anemia of CKD: a review[J]. Am J Kidney Dis, 2022, 79(6): 868-876. DOI: 10.1053/j.ajkd.2021.09.017.
[23] 邹羽真,梅丹.异麦芽糖酐铁和蔗糖铁对照研究的相关文献分析[J].临床药物治疗杂志, 2021, 19(8): 34-40. DOI: 10.3969/j.issn.1672-3384.2021.08.007.
[24] KUWASAWA-IWASAKI M, IO H, MUTO M, et al. Effects of L-carnitine supplementation in patients receiving hemodialysis or peritoneal dialysis[J]. Nutrients, 2020, 12(11): 3371. DOI: 10.3390/nu12113371.
[25] TAKASHIMA H, MARUYAMA T, ABE M. Significance of levocarnitine treatment in dialysis patients[J]. Nutrients, 2021, 13(4): 1219. DOI: 10.3390/nu13041219.
[26] PEKALA J, PATKOWSKA-SOKOŁA B, BODKOWSKI R, et al. L-carnitine: metabolic functions and meaning in humans life[J]. Curr Drug Metab, 2011, 12(7): 667-678. DOI: 10.2174/138920011796504536.
[27] SAWICKA A K, RENZI G, OLEK R A. The bright and the dark sides of L-carnitine supplementation: a systematic review[J]. J Int Soc Sports Nutr, 2020, 17(1): 49. DOI: 10.1186/s12970-020-00377-2.
[28] ZHU Y, XUE C, OU J H, et al. Effect of L-carnitine supplementation on renal Anemia in patients on hemodialysis: a meta-analysis[J]. Int Urol Nephrol, 2021, 53(10): 2149-2158. DOI: 10.1007/s11255-021-02835-5.
[29] 林辉.左卡尼汀联合重组人促红细胞生成素治疗血液透析患者肾性贫血效果观察[J].浙江医学, 2019, 41(15): 1665-1666, 1672. DOI: 10.12056/j.issn.1006-2785.2019.41.15.2018-614.
[30] 江春玲,郑强,邵维斌,等.rHuEPO皮下注射联合左卡尼汀用药对血透治疗并肾性贫血患者疗效与安全性的影响[J].医学理论与实践, 2021, 34(24): 4300-4301. DOI: 10.19381/j.issn.1001-7585.2021.24.033.
[31] 李静,李燕燕.左卡尼汀联合促红细胞生成素对维持性血液透析肾性贫血患者的临床疗效及心理状态的影响[J].国际精神病学杂志, 2021, 48(6): 1076-1079, 1105. DOI: 10.13479/j.cnki.jip.2021.06.033.
[32] 欧阳山丹,林珍,李阿云.左卡尼汀对维持性血液透析患者肾性贫血的疗效及心脏结构和功能的影响[J].贵州医科大学学报, 2019, 44(5): 601-605. DOI: 10.19367/j.cnki.1000-2707.2019.05.021.
[33] KLIGER A S, FOLEY R N, GOLDFARB D S, et al. KDOQI US commentary on the 2012 KDIGO clinical practice guideline for Anemia in CKD[J]. Am J Kidney Dis, 2013, 62(5): 849-859. DOI: 10.1053/j.ajkd.2013.06.008.
[34] 傅晓岑,任红,陈楠.肾性贫血的治疗研究[J].中国血液净化, 2022, 21(1): 6-9. DOI: 10.3969/j.issn.1671-4091.2022.01.002.
[35] KURATA Y, TANAKA T, NANGAKU M. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of Anemia in chronic kidney disease[J]. Curr Opin Nephrol Hypertens, 2020, 29(4): 414-422. DOI: 10.1097/MNH.0000000000000617.
[36] GUPTA N, WISH J B. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for Anemia in patients with CKD[J]. Am J Kidney Dis, 2017, 69(6): 815-826. DOI: 10.1053/j.ajkd.2016.12.011.
[37] HAASE V H. Hypoxia-inducible factor-prolyl hydroxylase inhibitors in the treatment of Anemia of chronic kidney disease[J]. Kidney Int Suppl, 2021, 11(1): 8-25. DOI: 10.1016/j.kisu.2020.12.002.
[38] DEL VECCHIO L, LOCATELLI F. Investigational hypoxia-inducible factor prolyl hydroxylase inhibitors(HIF-PHI)for the treatment of Anemia associated with chronic kidney disease[J]. Expert Opin Investig Drugs, 2018, 27(7): 613-621. DOI: 10.1080/13543784.2018.1493455.
[39] YASUOKA Y, IZUMI Y, FUKUYAMA T, et al. Effects of roxadustat on erythropoietin production in the rat body[J]. Molecules, 2022, 27(3): 1119. DOI: 10.3390/molecules27031119.
[40] LI Z L, TU Y, LIU B C. Treatment of renal Anemia with roxadustat: advantages and achievement[J]. Kidney Dis(Basel), 2020, 6(2): 65-73. DOI: 10.1159/000504850.
[41] DHILLON S. Roxadustat: first global approval[J]. Drugs, 2019, 79(5): 563-572. DOI: 10.1007/s40265-019-01077-1.
[42] CHEN N, HAO C M, LIU B C, et al. Roxadustat treatment for Anemia in patients undergoing long-term dialysis[J]. N Engl J Med, 2019, 381(11): 1011-1022. DOI: 10.1056/NEJMoa1901713.
[43] CHEN N, HAO C M, PENG X M, et al. Roxadustat for Anemia in patients with kidney disease not receiving dialysis[J]. N Engl J Med, 2019, 381(11): 1001-1010. DOI: 10.1056/NEJMoa1813599.
[44] ZHENG L, TIAN J H, LIU D P, et al. Efficacy and safety of roxadustat for anaemia in dialysis-dependent and non-dialysis-dependent chronic kidney disease patients: a systematic review and meta-analysis[J]. Br J Clin Pharmacol, 2022, 88(3): 919-932. DOI: 10.1111/bcp.15055.
[45] FISHBANE S, POLLOCK C A, EL-SHAHAWY M, et al. Roxadustat versus epoetin Alfa for treating Anemia in patients with chronic kidney disease on dialysis: results from the randomized phase 3 ROCKIES study[J]. J Am Soc Nephrol, 2022, 33(4): 850-866. DOI: 10.1681/ASN.2020111638.
[46] 李宏彬,梁军,马强.罗沙司他胶囊与重组人促红素治疗肾性贫血的效果及预后比较[J].中国医药导报, 2020, 17(8): 178-181.
[47] 康乐,周晶莹,郭夏楠,等.罗沙司他治疗慢性肾脏病5期非透析糖尿病肾脏疾病患者肾性贫血的疗效观察[J].中国实用内科杂志, 2022, 42(3): 238-241. DOI: 10.19538/j.nk2022030114.
[48] 丁嘉祥,甘红兵,杨清华,等.腹膜透析贫血合并炎症状态的诊治1例报告[J].中国实用内科杂志, 2020, 40(11): 964-965. DOI: 10.19538/j.nk2020110120.
[49] 康冬,尚进,武峰,等.罗沙司他对初始透析患者肾性贫血的疗效[J].肾脏病与透析肾移植杂志, 2020, 29(5): 420-425.
[50] 成水芹,周婷婷,张志宏,等.罗沙司他和重组人促红细胞生成素对腹膜透析患者血压及心脑血管并发症的影响[J].肾脏病与透析肾移植杂志, 2022, 31(1): 9-14. DOI: 10.3969/j.issn.1006-298X.2022.01.002.
[51] WIGERUP C, PÅHLMAN S, BEXELL D. Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer[J]. Pharmacol Ther, 2016, 164: 152-169. DOI: 10.1016/j.pharmthera.2016.04.009.
[52] KAPLAN J M, SHARMA N, DIKDAN S. Hypoxia-inducible factor and its role in the management of Anemia in chronic kidney disease[J]. Int J Mol Sci, 2018, 19(2): 389. DOI: 10.3390/ijms19020389.
[53] 黄凇崧,何常,严瑞.CD147和EGFR及HIF-1α在透明细胞肾细胞癌中的表达及意义[J].贵州医科大学学报, 2020, 45(6): 689-693, 732. DOI: 10.19367/j.cnki.2096-8388.2020.06.013.
[54] 寇宏博,韩冬冰,范以生,等.缺氧诱导因子1α、上皮钙粘附蛋白在肾透明细胞癌中表达及临床意义[J].临床军医杂志, 2020, 48(6): 649-652. DOI: 10.16680/j.1671-3826.2020.06.09.
[55] 王秋,林川,彭生才,等.肾癌患者血清VHL和HIF-1α与HIF-2α的表达及其与预后的相关性[J].西部医学, 2020, 32(7): 1053-1057. DOI: 10.3969/j.issn.1672-3511.2020.07.026.